Pacritinib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Pacritinib
Accession Number
DB11697
Type
Small Molecule
Groups
Investigational
Description

Pacritinib is under investigation for the prevention of Acute Myeloid Leukemia (AML).

Structure
Thumb
Synonyms
  • Pacritinib
  • Pacritinibum
External IDs
SB 1518 / SB-1518 / SB1518
Categories
UNII
G22N65IL3O
CAS number
937272-79-2
Weight
Average: 472.589
Monoisotopic: 472.247440906
Chemical Formula
C28H32N4O3
InChI Key
HWXVIOGONBBTBY-ONEGZZNKSA-N
InChI
InChI=1S/C28H32N4O3/c1-2-13-32(12-1)14-17-35-27-9-8-25-19-24(27)21-34-16-4-3-15-33-20-22-6-5-7-23(18-22)26-10-11-29-28(30-25)31-26/h3-11,18-19H,1-2,12-17,20-21H2,(H,29,30,31)/b4-3+
IUPAC Name
(16E)-11-[2-(pyrrolidin-1-yl)ethoxy]-14,19-dioxa-5,7,27-triazatetracyclo[19.3.1.1^{2,6}.1^{8,12}]heptacosa-1(25),2(27),3,5,8,10,12(26),16,21,23-decaene
SMILES
C(CN1CCCC1)OC1=CC=C2NC3=NC=CC(=N3)C3=CC(COC\C=C\COCC1=C2)=CC=C3

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
3,5-diiodothyropropionic acidThe therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Pacritinib.
3,5-DiiodotyrosineThe therapeutic efficacy of 3,5-Diiodotyrosine can be decreased when used in combination with Pacritinib.
AbaloparatideThe therapeutic efficacy of Abaloparatide can be decreased when used in combination with Pacritinib.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Pacritinib.
BenzylthiouracilThe therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with Pacritinib.
CarbimazoleThe therapeutic efficacy of Carbimazole can be decreased when used in combination with Pacritinib.
DibromotyrosineThe therapeutic efficacy of Dibromotyrosine can be decreased when used in combination with Pacritinib.
ElcatoninThe therapeutic efficacy of Elcatonin can be decreased when used in combination with Pacritinib.
FollitropinThe therapeutic efficacy of Follitropin can be decreased when used in combination with Pacritinib.
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Pacritinib.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
46216796
PubChem Substance
347828062
ChemSpider
28518965
BindingDB
50210177
ChEMBL
CHEMBL2035187
HET
6T3
Wikipedia
Pacritinib
PDB Entries
5lbz

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableAgnogenic Myeloid Metaplasia1
1CompletedNot AvailableDrug-drug Interaction Study1
1CompletedNot AvailableHealthy Volunteers5
1CompletedOtherAgnogenic Myeloid Metaplasia1
1CompletedTreatmentLymphoma, B Cell / Lymphoma, Hodgkins / Malignant Lymphomas1
1CompletedTreatmentRecurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia (Secondary AML, sAML) / Therapy-Related Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
1Not Yet RecruitingTreatmentAgnogenic Myeloid Metaplasia / Atypical Chronic Myeloid Leukemia / Chronic Myelomonocytic Leukemia / Juvenile Myelomonocytic Leukemia / Myelodysplastic Syndromes / Myeloproliferative Neoplasms1
1RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Lymphoma, T-Cell, Cutaneous / Lymphoma, T-Cell, Peripheral / Lymphoplasmacytic Lymphoma / Lymphoproliferative Disorders / Mantle Cell Lymphoma (MCL) / Waldenström's Macroglobulinemia (WM)1
1TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2CompletedTreatmentAcute Myelogenous Leukaemia (AML) / Agnogenic Myeloid Metaplasia / Chronic Chronic myelogenous leukemia / Chronic Myelomonocytic Leukemia / Myelodysplastic Syndromes1
1, 2CompletedTreatmentAgnogenic Myeloid Metaplasia / Essential Thrombocythemia (ET) / Myeloproliferative Disorders / Polycythemia Vera (PV)1
1, 2RecruitingPreventionGraft Versus Host Disease (GVHD) / Lung Cancers1
1, 2WithdrawnTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma1
2Active Not RecruitingTreatmentColorectal Cancers1
2Active Not RecruitingTreatmentPost Essential Thrombocythemia Myelofibrosis / Post Polycythemia Vera Myelofibrosis / Primary Myelofibrosis1
2CompletedTreatmentIndolent Lymphoma / Lymphoma, Hodgkins / Mantle Cell Lymphoma (MCL)1
2RecruitingTreatmentAgnogenic Myeloid Metaplasia1
2TerminatedPreventionLeukemia Acute Myeloid Leukemia (AML)1
2TerminatedTreatmentLeukemias2
2TerminatedTreatmentMyeloproliferative Disorders1
2WithdrawnTreatmentPrimary Myelofibrosis1
3TerminatedTreatmentPost Essential Thrombocythemia Myelofibrosis / Post Polycythemia Vera Myelofibrosis / Primary Myelofibrosis2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0381 mg/mLALOGPS
logP4.78ALOGPS
logP4.58ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)14.1ChemAxon
pKa (Strongest Basic)8.86ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area68.74 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity139.43 m3·mol-1ChemAxon
Polarizability52.32 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenol ethers
Sub Class
Not Available
Direct Parent
Phenol ethers
Alternative Parents
Alkyl aryl ethers / Pyrimidines and pyrimidine derivatives / N-alkylpyrrolidines / Heteroaromatic compounds / Trialkylamines / Oxacyclic compounds / Dialkyl ethers / Azacyclic compounds / Hydrocarbon derivatives
Substituents
Phenol ether / Alkyl aryl ether / Pyrimidine / N-alkylpyrrolidine / Heteroaromatic compound / Pyrrolidine / Tertiary amine / Tertiary aliphatic amine / Dialkyl ether / Ether
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 14:40 / Updated on January 14, 2020 07:25